Betamethasone butyrate propionate/maxacalcitolAlternative Names: M 8010; M 801801; Marduox; Maxacalcitol/betamethasone butyrate propionate
Latest Information Update: 29 Mar 2016
At a glance
- Originator Chugai Pharmaceutical; Maruho
- Developer Maruho
- Class Analgesics; Anti-inflammatories; Antipruritics; Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Small molecules
- Mechanism of Action Steroid receptor antagonists; Vitamin D3 stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Registered Plaque psoriasis